Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces Allowance of Key Patent for its Circulating Tumor Cell Platform
Biocept Announces Allowance of Key Patent for its Circulating Tumor Cell Platform San Diego, California: ? Biocept, Inc., a privately?held CLIA?certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in blood samples from cancer patients,
View HTML
Toggle Summary Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients
Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
View HTML
Toggle Summary Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
View HTML
Toggle Summary Biocept, Inc. announces availability of its new breast cancer test, OncoCEE-BR™ utilizing circulating tumor cells (CTCs)
Biocept, Inc. announces availability of its new breast cancer test, OncoCEE-BR™ utilizing circulating tumor cells (CTCs) Capture, detection and enumeration Determination of HER2/neu status Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the
View HTML
Toggle Summary Biocept, Inc. announces new CFO
Biocept, Inc. announces new CFO Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company’s accounting, finance, treasury, investor relations, risk
View HTML
Toggle Summary Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)
Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago,
View HTML
Toggle Summary Biocept, Inc. Announces Peer Reviewed Article in Journal of Oncology
Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
View HTML
Toggle Summary Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team
Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team SAN DIEGO / — Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept’s Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr.
View HTML
Toggle Summary David F. Hale and Ivor Royston, M.D. Join Biocept Board
David F. Hale and Ivor Royston, M.D. Join Biocept Board The Board of Biocept, Inc. announced today that David F. Hale has joined the Board as Executive Chairman and Ivor Royston, M.D. as a Director. Mr. Hale and Dr. Royston first worked together at Hybritech, San Diego’s first biotech company, of
View HTML
Toggle Summary Biocept, Inc. Announces New Director Appointment
Biocept, Inc. Announces New Director Appointment Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director. “We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of
View HTML